化工儀器網(wǎng)
技術(shù)文章
小分子抑制劑：1173699-31-4；AMG-337
閱讀：613 發(fā)布時間：2019-3-31中文名稱：AMG-337
英文名稱：AMG337
CAS：1173699-31-4
其他名稱：AMG-337;6-[(1R)-1-[8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one;(R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one
分子式：C23H22N7O3F
分子量：463.464
外 觀：固態(tài)粉末
結(jié)構(gòu)式：
供應(yīng)商：陜西新研博美生物科技有限公司
TELE： 請點(diǎn)擊此處進(jìn)入陜西新研博美生物科技有限公司展臺查看
MOBLE：請點(diǎn)擊此處進(jìn)入陜西新研博美生物科技有限公司展臺查看
| A-674563 | (ALPHAS)-ALPHA-[[[5-(3-甲基-1H-吲唑-5-基)-3-吡啶基]氧]甲基]苯乙胺 | 552325-73-2 |
| A966492 | 2-[2-氟-4-[(2S)-2-吡咯烷基]苯基]-1H-苯并咪唑-7-甲酰胺 | 931462-61-5 |
| ABT-199 | ABT-199 | 1257044-40-8 |
| ABT-639 | ABT-639 | 1235560-28-7 |
| ABT-888 | 2-[(2R)-2-甲基-2-吡咯烷基]-1H-苯并咪唑-7-甲酰胺 | 912444-00-9 |
| AC220 | N-(5-叔丁基異惡唑-3-基)-N'-{4-[7-[2-(嗎啉-4-基)乙氧基]咪唑并[2,1-B][1,3]苯并噻唑-2-基]苯基}脲 | 950769-58-1 |
| Acalabrutinib/ACP-196 | ACP-196 | 1420477-60-6 |
| ACT-678689 | ACT-678689 | 1783256-96-1 |
| ACY-1215 | ACY1215 | 1316214-52-4 |
| 2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide | N/A | 1316215-12-9 |
| AG-120 | RG120 | 1448347-49-6 |
| AGI-5198 | AGI-5198 (IDH-C35) | 1355326-35-0 |
| Akti-1/2 | 1,3-二氫-1-[1-[[4-(6-苯基-1H-咪唑并[4,5-G]喹喔啉-7-基)苯基]甲基]-4-哌啶基]-2H-苯并咪唑-2-酮 | 612847-09-3 |
| AMG319 | AMG319 | 1608125-21-8 |
| Finafloxacin Hydrochloride | 非那沙星 | 209342-41-6 |
| Tivozanib (AV-951) | 替沃扎尼 | 475108-18-0 |
| Saracatinib | 塞卡替尼 | 379231-04-6 |
| AZD2014 | AZD2014 | 1009298-59-2 |
| azd2932 | AZD2932 | 883986-34-3 |
| AZD-4547 | AZD-4547 | 1035270-39-3 |
| AZD6244 | 司美替尼 | 606143-52-6 |
| AZD6738 | AZD6738 | 1352226-88-0 |
| BAF312 | 辛波莫德 | 1230487-00-9 |
| BAY85-3934 | MOLIDUSTAT | 1154028-82-6 |
| Binimetinib (MEK-162, ARRY-162, ARRY-438162) | 5-[(4-溴-2-氟苯基)氨基]-4-氟-N-(2-羥基乙氧基)-1-甲基-1H-苯并咪唑-6-甲酰胺 | 606143-89-9 |
| BLU-9931 | BLU 9931 | 1538604-68-0 |
| BLZ945 | BLZ945 | 953769-46-5 |
| BML-277 | 2-(4-(4-CHLOROPHENOXY)PHENYL)-1H-BENZO[D]IMIDAZOLE-5-CARBOXAMIDE | 516480-79-8 |
| BMS309403 | [2'-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]-ACETIC ACID | 300657-03-8 |
| BMS754807 | BMS-754807 | 1001350-96-4 |
| BMS777607 | BMS 777607 | 1196681-44-3 |
| BMS-794833 | BMS-794833 | 1174046-72-0 |
| BMS833923 | BMS-833923 | 1059734-66-5 |
| BTZ043 | 2-[(2S)-2-甲基-1,4-二氧雜-8-氮雜螺[4.5]癸烷-8-基]-8-硝基-6-三氟甲基-4H-1,3-苯并噻嗪-4-酮 | 1161233-85-7 |
| BX795 | N-[3-[[5-碘-4-[[3-[(2-噻吩基羰基)氨基]丙基]氨基]-2-嘧啶基]氨基]苯基]-1-吡咯烷甲酰胺 | 702675-74-9 |
| BX-912 | BX-912 | 702674-56-4 |
| Alpelisib(BYL719 | (2S)-N1-[4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基乙基)-4-吡啶基]-2-噻唑基]-1,2-吡咯烷二甲酰胺 | 1217486-61-7 |
| C646 | C646 | 328968-36-1 |
| CA-074ME | L-TRANS-環(huán)氧琥珀酸- ILE-PRO-OME丙醛 | 147859-80-1 |
| CAY10683 | ETHYL 4-OXO-4-(PHENETHYLAMINO)BUTYLCARBAMATE | 1477949-42-0 |
| CB5083 | CB5083 | 1542705-92-9 |
| CC-223 | CC-223 | 1228013-30-6 |
| C-DIM12 | N/A | 178946-89-9 |
| CGI-1746 | N-[3-[4,5-二氫-4-甲基-6-[[4-(4-嗎啉基羰基)苯基]氨基]-5-氧代-2-吡嗪基]-2-甲基苯基]-4-(叔丁基)苯甲酰胺 | 910232-84-7 |
| ch5132799 | [5-[7-甲磺?；?2-(嗎啉-4-基)-6,7-二氫-5H-吡咯并[2,3-D]嘧啶-4-基]嘧啶-2-基]胺 | 1007207-67-1 |
| CNX-2006 | CNX2006 | 1375465-09-0 |
| Crenolanib (CP-868596) | Crenolanib (CP-868596) | 670220-88-9 |
| CUDC-101 | 7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羥基庚酰胺 | 1012054-59-9 |
| CX-4945 | 1009820-21-6 | |
| CYC-116 | CYC-116 | 693228-63-6 |
| ROSCOVITINE | 細(xì)胞周期蛋白B激酶抑制劑 | 186692-46-6 |
| Cyclopamine | 環(huán)杷明 | 4449-51-8 |
| N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide | momelotinib（CYT-387） | 1056634-68-4 |
| CZC-25146 | CZC25146 | 1191911-26-8 |
| DBeQ | DBEQ | 177355-84-9 |
| DCC2701 | ALTIRATINIB | 1345847-93-9 |
| Defactinib (VS-6063, PF-04554878) | DEFACTINIB (VS-6063, PF-04554878) | 1345713-71-4 |
| EHop-016 | EHOP-016;N4-(9-ETHYL-9H-CARBAZOL-3-YL)-N2-(3-MORPHOLIN-4-YL-PROPYL)-PYRIMIDINE-2,4-DIAMINE | 1380432-32-5 |
| Pelitinib(EKB-569) | 培利替尼（Pelitinib） | 257933-82-7 |
| EMD-1214063 | Tepotinib(EMD 1214063) | 1100598-32-0 |
| EPz6438 | EPZ6438 | 1403254-99-8 |
| FIPI | FIPI | 939055-18-2 |
| FUB359 | Ciproxifan | 184025-18-1 |
| G-749 | G-749 | 1457983-28-6 |
| GDC-0032 | GDC 0032 | 1282512-48-4 |
| GDC-0084 | GDC-0084 | 1382979-44-3 |
| XL518,GDC-0973 | 考比替尼 | 934660-93-2 |
| GKT137831 | N/A | 1218942-37-0 |
| gne7915 | GNE7915 | 1351761-44-8 |
| GNF-7 | GNF-7 | 839706-07-9 |
| GSK0660 | GSK0660 | 1014691-61-2 |
| N-[6-[6-Chloro-5-[[(4-fluorophenyl)sulfonyl]aMino]-3-pyridinyl]-1,3-benzothiazol-2-yl]acetaMide | N-[6-[6-氯-5-[[(4-氟苯基)磺酰基]氨基]-3-吡啶基]-1,3-苯并噻唑-2-基]乙酰胺 | 1112980-86-5 |
| GSK163090 | GSK163090 | 844903-58-8 |
| GSK2126458 | GSK2126458; GSK-2126458 | 1086062-66-9 |
| gsk2269557HCL | GSK2269557 | 1254036-77-5 |
| gsk2292767 | GSK2292767 | 1254036-66-2 |
| GSK2636771 | GSK2636771 | 1372540-25-4 |
| GSK2838232A | GSK2838232 | 1443461-21-9 |
| GSK3787 | GSK-3787 | 188591-46-0 |
| GSK591 (EPZ015866,GSK3203591) | GSK591 (EPZ-015866) | 1616391-87-7 |
| GSKJ1 | N-[2-(2-吡啶基)-6-(1,2,4,5-四氫-3H-3-苯并氮雜卓-3-基)-4-嘧啶基]-BETA-丙氨酸 | 1343722-53-7 |
| GSKJ4 | N-[2-(2-吡啶基)-6-(1,2,4,5-四氫-3H-3-苯并氮雜卓-3-基)-4-嘧啶基]-BETA-丙氨酸乙酯 | 1373423-53-0 |
| GZD824 | GZD824DIMESYLATE | 1421783-64-3 |
| HS-173 | HS-173 | 1276110-06-5 |
| 2-[(6-Amino-9H-purin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone | 2-[(6-氨基-9H-嘌呤-9-基)甲基]-5-甲基-3-(2-甲基苯基)-4(3H)-喹唑啉酮 | 371242-69-2 |
| ICG-001 | ICG-001 | 847591-62-2 |
| MPEP | ?？颂婺?/span> | 610798-31-7 |
| 5-(4-aMi-isopropyl-1H-pyrazolo[3,4-d]pyriMidin-3-yl)benzo[d]oxazol-2-aMine | 3-(2-氨基-5-苯并惡唑基)-1-(1-甲基乙基)-1H-吡唑并[3,4-D]嘧啶-4-胺 | 1224844-38-5 |
| FG-4592 | 羅沙司他 | 808118-40-3 |
| BMS863233(salt) | XL413 (BMS-863233) | 1169562-71-3 |
| ACTB-1003 | ACTB-1003 | 939805-30-8 |
| APY29 | APY29 | 1216665-49-4 |
| IWR-1 | IWR-1 | 1127442-82-3 |